Mercados españoles abiertos en 4 hrs 59 min

AbbVie Inc. (ABBV)

NYSE - NYSE Precio demorado. Divisa en USD
Añadir a la lista de favoritos
158,20-0,23 (-0,15%)
Al cierre: 04:03PM EST
157,15 -1,05 (-0,66%)
Después del cierre: 07:59PM EST

AbbVie Inc.

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
847 932 7900
https://www.abbvie.com

Sector(es)Healthcare
SectorDrug Manufacturers—General
Empleados a tiempo completo50.000

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Richard A. GonzalezChairman & CEO7,42M19,91M1954
Mr. Robert A. MichaelVice Chairman & Pres3,82MN/A1970
Ms. Laura J. SchumacherVice Chairman of External Affairs & Chief Legal Officer4,18M13,28M1963
Mr. Jeffrey Ryan StewartExec. VP & Chief Commercial Officer3,25MN/A1969
Mr. Scott T. ReentsSr. VP & CFON/AN/A1967
Dr. Azita Saleki-Gerhardt Ph.D.Exec. VP of OperationsN/AN/A1963
Dr. Thomas J. HudsonSr. VP of R&D and Chief Scientific OfficerN/AN/A1962
Ms. Elizabeth SheaVP of Investor RelationsN/AN/AN/A
Mr. Perry C. SiatisExec. VP, Gen. Counsel & Sec.N/AN/AN/A
Mr. Timothy J. RichmondExec. VP & Chief HR OfficerN/AN/A1966
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Gobierno corporativo

El ISS Governance QualityScore de AbbVie Inc., a día 28 de noviembre de 2022, es 8. Las puntuaciones base son Auditoría: 9; Tablero: 5; Derechos de los accionistas: 9; Compensación: 3.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.